TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial – P&T Community

By raymumme

TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial
P&T Community
Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product candidate, AlloCSC-01, is currently in a Phase II clinical trial in Acute Myocardial Infarction (AMI). In addition, the second product candidate from the cardiac stem ...

and more »

See the original post here:
TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial - P&T Community

Related Post


categoriaCardiac Stem Cells commentoComments Off on TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial – P&T Community | dataMarch 10th, 2017

About...

This author published 822 posts in this site.
Teacher, Educator, Speaker, Adult Stem Cell Advocate

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024